Attosecond pulses enable sub-femtosecond studies of ultrafast electron dynamics. Since 2001, pulse durations have shortened ...

SHANNON, CLARE, IRELAND, February 27, 2026 /EINPresswire.com/ -- Announcing a new publication from Opto-Electronic ...

Septerna is poised for a pivotal catalyst with upcoming Phase 1 data for SEP-631, targeting mast cell-driven diseases via ...

Namodenoson (CF102), an investigational small-molecule A3 adenosine receptor (A3AR) agonist, has demonstrated favorable ...

Kyowa Kirin has decided to discontinue all clinical development of its OX40 drug after two new cancer cases emerged. | Kyowa Kirin has decided to discontinue all clinical development of its OX40 drug ...

Company Initiates Regulatory Discussions with CDSCO; Plans 408-Patient Pivotal Study Targeting Standard-Risk Several Viral Infected ...

Fecal microbiota transplants may enhance patients’ response to immunotherapy, but experts caution that the latest data remain proof-of-concept and far from practice-changing.

The MarketWatch News Department was not involved in the creation of this content.-- Cebranopadol is an investigational first-of-its kind dual NOP/MOP receptor (NMR) agonist which ...

CNP-104 improved key cholestasis endpoints at one year, including a composite serum alkaline phosphatase (ALP) and bilirubin biochemical responseDurable effects observed across liver stiffness, ...

Espoo, Finland, March 5, 2026: Herantis Pharma Plc ("Herantis") a clinical-stage company developing disease-modifying therapies to stop the progression of Parkinson’s disease, releases today the ...

The recent safety update led Kyowa Kirin and Amgen to conclude potential risks may outweigh benefits for patient populations.

Scientists in China have developed a metasurface platform that realizes true three-dimensional (3D) vectorial holography by ...